Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1964 1
1972 1
1980 1
1984 1
1985 2
1986 2
1987 3
1988 2
1989 7
1990 6
1991 5
1992 6
1993 5
1994 5
1995 3
1996 4
1997 1
1998 2
1999 1
2000 3
2001 1
2002 4
2003 3
2004 5
2005 7
2006 6
2007 10
2008 5
2009 4
2010 2
2011 4
2012 5
2013 4
2014 9
2015 6
2016 9
2017 6
2018 10
2019 14
2020 12
2021 4
2022 8
2023 9
2024 5
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

200 results

Results by year

Filters applied: . Clear all
Page 1
TIGIT blockade repolarizes AML-associated TIGIT+ M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis.
Brauneck F, Fischer B, Witt M, Muschhammer J, Oelrich J, da Costa Avelar PH, Tsoka S, Bullinger L, Seubert E, Smit DJ, Bokemeyer C, Ackermann C, Wellbrock J, Haag F, Fiedler W. Brauneck F, et al. Among authors: ackermann c. J Immunother Cancer. 2022 Dec;10(12):e004794. doi: 10.1136/jitc-2022-004794. J Immunother Cancer. 2022. PMID: 36549780 Free PMC article.
Immunosuppressive M2 TAMs represent a promising target population to enhance phagocytosis of ovarian cancer cells in vitro.
Brauneck F, Oliveira-Ferrer L, Muschhammer J, Sturmheit T, Ackermann C, Haag F, Schulze Zur Wiesch J, Ding Y, Qi M, Hell L, Schmalfeldt B, Bokemeyer C, Fiedler W, Wellbrock J. Brauneck F, et al. Among authors: ackermann c. Front Immunol. 2023 Oct 2;14:1250258. doi: 10.3389/fimmu.2023.1250258. eCollection 2023. Front Immunol. 2023. PMID: 37876933 Free PMC article.
[The problem of long/post-COVID in expert assessments].
Eyfferth T, Koczulla AR, Freytag HW, Krahl G, Ackermann C, Bultmann S, Reimertz R, Dresing K; Sektion Begutachtung der DGOU. Eyfferth T, et al. Among authors: ackermann c. Unfallchirurgie (Heidelb). 2023 May;126(5):373-386. doi: 10.1007/s00113-023-01297-x. Epub 2023 Apr 20. Unfallchirurgie (Heidelb). 2023. PMID: 37079057 Free PMC article. Review. German.
First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17.
Mark M, Froesch P, Gysel K, Rothschild SI, Addeo A, Ackermann CJ, Chiquet S, Schneider M, Ribi K, Maranta AF, Bastian S, von Moos R, Joerger M, Früh M; Swiss Group for Clinical Cancer Research (SAKK). Mark M, et al. Among authors: ackermann cj. Eur J Cancer. 2024 Mar;200:113600. doi: 10.1016/j.ejca.2024.113600. Epub 2024 Feb 5. Eur J Cancer. 2024. PMID: 38330766 Free article. Clinical Trial.
Economic burden of psoriatic arthritis.
Ackermann C, Kavanaugh A. Ackermann C, et al. Pharmacoeconomics. 2008;26(2):121-9. doi: 10.2165/00019053-200826020-00003. Pharmacoeconomics. 2008. PMID: 18198932 Review.
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Huober J, Weder P, Ribi K, Thürlimann B, Thery JC, Li Q, Vanlemmens L, Guiu S, Brain E, Grenier J, Dalenc F, Levy C, Savoye AM, Müller A, Membrez-Antonioli V, Gérard MA, Lemonnier J, Hawle H, Dietrich D, Boven E, Bonnefoi H; Swiss Group for Clinical Cancer Research, Unicancer Breast Group, and Dutch Breast Cancer Research Group. Huober J, et al. JAMA Oncol. 2023 Oct 1;9(10):1381-1389. doi: 10.1001/jamaoncol.2023.2909. JAMA Oncol. 2023. PMID: 37561451 Free PMC article. Clinical Trial.
200 results